Skip to podcast content

GLP-1 Hub Podcast

GLP-1s and Heart Health: What to Monitor Beyond Weight

By the GLP-1 Hub editorial teamArticle published With Michelle Routhenstein, RDEpisode released August 18, 2025

Cardiovascular dietitian Michelle Routhenstein discusses cholesterol, blood pressure and nourishment when a GLP-1 changes your appetite.

Listen to this episode

The GLP-1 Hub Podcast

Open episode on Buzzsprout

Ana Reisdorf brings a surprising observation to this conversation: after losing 40 pounds while taking a GLP-1, her cholesterol had gone up. It is a useful reminder that a change on the scale does not tell you everything about your heart health.

Cardiovascular dietitian Michelle Routhenstein describes a broader approach: know the measures that matter for your risk, make sure a smaller appetite still leaves room for nourishment, and address symptoms rather than accepting them as the cost of treatment. Her discussion offers practical ways to prepare for a nutrition or medical appointment without assuming that every change has one explanation.

What does the evidence say about GLP-1s and heart health?

There is real cardiovascular-outcome evidence for certain medicines and patient groups. In March 2024, the FDA approved Wegovy, semaglutide injection, to reduce cardiovascular death, heart attack and stroke in adults with established cardiovascular disease and overweight or obesity.

In the trial supporting that indication, the combined outcome occurred in 6.5% of participants receiving Wegovy and 8% receiving placebo. Both groups also received usual medical treatment and lifestyle counseling. Those results show an additional benefit within care, not a reason to stop treating blood pressure or cholesterol.

The population matters. This finding does not establish that every GLP-1 medicine prevents a first heart attack in every person, or that someone without known cardiovascular disease will receive the same benefit. Ask your prescriber what evidence applies to your actual medication and medical history, and what the treatment is intended to do for you.

Follow your heart-risk measures alongside your weight

Routhenstein points out that cardiovascular problems can develop without an obvious change in appearance. Looking fit or losing weight cannot replace checking blood pressure and appropriate blood tests.

Bring previous results to the appointment, including dates. A clinician can interpret your lipid panel, blood pressure and glucose measures in the context of family history, existing disease and other medicines. Ask which changes would call for action and when to repeat testing. The interview’s discussion of additional tests is not a requirement that every listener order the same panel.

The American Heart Association explains that LDL goals depend on individual risk. A result that looks acceptable on a laboratory report may not be your treatment goal, especially if you already have cardiovascular disease. Conversely, one unusual result needs interpretation rather than a self-diagnosis.

If your clinician recommends home blood-pressure monitoring, make the readings useful. The AHA recommends a validated upper-arm monitor with a correctly fitting cuff, quiet rest before measurement and recording readings over time. Bring the device to an appointment to check technique. Do not stop blood-pressure medicine on the strength of a lower home reading without speaking with the prescriber.

When appetite shrinks, think beyond protein

One of Routhenstein’s recurring concerns is the person whose appetite has fallen so far that one meal becomes the whole day’s food. Reduced food noise can feel welcome, but having little desire to eat does not demonstrate that the body is receiving what it needs.

She suggests starting with foods that provide several nutrients at once. Yogurt, lentils and fish are examples from the interview, rather than separate products for every mineral. Depending on what you tolerate, that might mean yogurt with fruit, a small lentil soup, or fish with a manageable portion of vegetables and a grain. These are meal-building ideas, not a guarantee that any one plate covers a day’s needs.

The AHA’s 2026 dietary guidance emphasizes an overall eating pattern: varied fruits and vegetables, whole grains, suitable protein sources and unsaturated fats in place of saturated fats. With a smaller appetite, the question becomes how to keep that variety achievable in the portions you can manage.

A dietitian can review an ordinary day’s intake and help you find workable additions. If nausea means breakfast disappears, or fullness makes vegetables difficult, start with that specific problem. More restriction is not automatically a better heart-health plan. Ana’s discussion of building meals on a GLP-1 offers related practical food combinations.

If cholesterol rises, investigate rather than guessing

Ana asks whether constipation might explain her higher cholesterol. The conversation moves between bowel habits, fiber and the saturated-fat content of a protein-focused diet. These are useful topics to bring to a review, but the exchange does not establish why her result changed.

The AHA describes several influences on LDL, including family history, eating habits and other health conditions. A clinician can review what changed, whether another test is needed and which treatment fits your risk. Do not assume that the injection caused the increase, or that resolving constipation will normalize cholesterol.

For nutrition, look at the foods making up the protein total. A routine built mainly around fatty meats and large amounts of cheese differs from one that also includes beans, fish and other options. The AHA’s guidance supports replacing sources of saturated fat with sources of unsaturated fat; it does not require abandoning protein.

Constipation also deserves attention in its own right. Routhenstein discusses gradual changes in fiber, fluids and movement. NIDDK constipation guidance supports food, fluid and activity changes and describes clinician-selected medicines when needed. Follow any prescribed fluid limit, and ask for help if symptoms persist instead of continuing to add fiber or supplements on your own.

Make supplement decisions specific to the gap

Routhenstein does not recommend one supplement for everyone taking a GLP-1. She distinguishes a person who is eating varied meals from someone whose intake or clinical assessment identifies a particular problem. A smaller appetite is a reason to assess nutrition, not automatic evidence of a deficiency.

Potassium is a good example of why individual advice matters. It comes from many foods, but adding more is not appropriate for everyone. NIH’s Office of Dietary Supplements warns that kidney disease and certain medicines can raise the risk of excessive blood potassium. Ask before adding potassium supplements or potassium-based salt substitutes, particularly if you take heart or blood-pressure medicines.

Bring all supplement labels to the review, including powders, gummies and products marketed for digestion. Ask what need each one addresses and whether it overlaps with another product. An unusual result from a commercial hair test is not, by itself, a diagnosis or a reason to begin a supplement regimen.

Tell the care team when symptoms interfere with eating or daily life

The final message from Routhenstein is to avoid ignoring symptoms. Persistent nausea, reflux or diarrhea affects quality of life and may make it harder to eat and drink adequately. Nutrition support can be part of the response, alongside appropriate medical assessment.

Benefits and adverse effects can coexist. The Wegovy prescribing information, revised June 2026, describes sometimes severe gastrointestinal reactions, kidney injury associated with dehydration, and increases in resting heart rate. It advises reporting persistent gastrointestinal symptoms and palpitations or a racing heartbeat at rest. This is not a reason to diagnose a heart rhythm problem from indigestion; it is a reason to describe symptoms promptly and get appropriate help.

Do not try to solve a persistent racing heartbeat, inability to maintain fluids or significant illness with a new food or supplement. Contact the medical team. Dr. Harry Oken’s GLP-1 side-effect discussion provides a companion conversation about taking symptoms seriously.

Leave with a plan for the whole picture

Before your next visit, gather three things: your recent results, a realistic picture of what you are eating, and a short description of symptoms that are getting in the way. Then ask which measures matter most for your risk, what nutrition support would help and when you will review progress.

You can welcome a medicine’s benefit and still ask for better symptom control or more help with meals. Routhenstein’s most useful point is that nourishment, function and heart-risk follow-up belong in the same conversation. A lower weight should open that conversation, not end it.